Breast Cancer - Female
Conditions
Keywords
AK112 combining chemothrapy, neoadjuvant therapy, TNBC
Brief summary
This prospective, multicenter, single-arm clinical study aims to evaluate the efficacy and safety of AK112 in combination with albumin-bound paclitaxel and carboplatin as neoadjuvant treatment in adult women with early or locally advanced triple-negative breast cancer (TNBC). The study seeks to address the pathological complete response (pCR) rate, objective response rate (ORR), breast conservation rate, and invasive disease-free survival (iDFS) following treatment with AK112 combined with albumin-bound paclitaxel and carboplatin in early or locally advanced TNBC.
Interventions
The combination of AK112, a platinum-based chemotherapy agent, and Paxlitaxel is administered every three weeks as a neoadjuvant treatment for triple-negative breast cancer. After completing six cycles of this regimen, the participant undergoes surgical treatment.
Sponsors
Shuangyue Liu
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntary Participation and Informed Consent: The participant voluntarily agrees to join this clinical trial, signs a written informed consent form, understands the study, and is willing to comply with all trial procedures. 2. Eligibility by Age and Gender: Female participants aged ≥18 years and ≤75 years on the day of signing the informed consent form. 3. Pathological Confirmation of Disease: Histopathologically confirmed diagnosis of T1-4N0-3M0 (except for T1N0M0) triple-negative invasive breast cancer, defined as negative for estrogen receptor (ER) and progesterone receptor (PgR) (immunohistochemistry: ER, PR \< 1%), and human epidermal growth factor receptor 2 (HER2) (immunohistochemistry HER2 0\ 1+; or immunohistochemistry HER2 2+ with no amplification on HER2 FISH gene testing). 4. Measurable Lesion: At least one lesion measurable according to RECIST v1.1 criteria. Participants diagnosed at an external institution agree to provide archived or freshly obtained tumor tissue samples (formalin-fixed paraffin-embedded \[FFPE\] tissue blocks or at least 25 unstained tumor tissue slides) for pathology review. 5. Planned Surgical Treatment: Participants are scheduled to undergo definitive surgical resection of breast cancer, including either breast-conserving surgery or mastectomy, along with sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND), and are planned to receive neoadjuvant chemotherapy.
Exclusion criteria
1. Prior Anti-Cancer Treatments. 2. Received systemic anti-cancer treatment, including chemotherapy, radiotherapy, immunotherapy, targeted therapy (within 2 weeks for small molecule targeted therapies), or biological agent treatment within 4 weeks before enrollment. 3. Received palliative local treatments within 2 weeks before enrollment. 4. Received systemic non-specific immune modulatory treatments (e.g., interleukins, interferons, thymopeptides) within 2 weeks before enrollment. 5. Received traditional Chinese medicine or Chinese patent medicines with anti-cancer indications within 2 weeks before enrollment. 6. Prior PD-1/PD-L1 Treatment. 7. Previously received treatment with PD-1 inhibitors or PD-L1 inhibitors. 8. Concurrent Participation in Other Clinical Studies. 9. Currently participating in another clinical study, unless it is an observational, non-interventional study or the follow-up period of an interventional study. 10. History of Other Malignancies: (1) Has a history of other malignant tumors within 5 years prior to enrollment or concurrently, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, and thyroid cancer. (2) Active Autoimmune Diseases: Has active autoimmune diseases that required systemic treatment (such as corticosteroids) within 2 years before enrollment, or has autoimmune diseases that the investigator judges may recur or require planned treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pCR | After surgery, within an average of 2 weeks | pathological complete response |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Two weeks after completing 6 cycles of neoadjuvant therapy (each cycle is 21 days) | After complete 6 cycles of neoadjuvant chemotherapy in combination with AK112 |
Contacts
Primary ContactTing Luo
Outcome results
None listed